Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 11Completed 10Not yet recruiting 7Unknown 5Active not recruiting 5Terminated 3Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Maintenance × Clear all
NCT04542824 2026-05-05

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04881838 2026-03-19

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Children's Cancer Group, China

Phase 3 Active not recruiting
172 enrolled
Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

Children's Cancer Group, China

Phase 3 Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07199855 2025-09-30

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Zhejiang University

Phase 2 Active not recruiting
24 enrolled
Lymphoid

Burkitt Lymphoma

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Chinese PLA General Hospital

Phase 1 Active not recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡